Mommox (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress the release of inflammatory cytokines, chemokines, and other mediators. This reduces swelling, mucus production, and irritation in the nasal cavity.

The specific dose and frequency of Mommox are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing Mommox to pregnant or nursing individuals. Consultation with a physician is essential.

To request Mommox, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mommox (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic absorption profile, similar to fluticasone propionate. Clinical studies suggest comparable efficacy in symptom control, while its once‑daily dosing may offer convenience over some alternatives.

Mommox should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed when not in use and keep it out of reach of children.

Mommox is administered as a nasal spray. The recommended technique is to gently blow the nose, insert the nozzle into one nostril while keeping the other closed, and spray the prescribed number of sprays. Repeat in the opposite nostril if directed by the prescriber.

Serious adverse events, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, and adrenal suppression with prolonged high‑dose use. Patients should seek immediate medical attention if they experience unusual bleeding, persistent nasal pain, or signs of systemic corticosteroid effects.

Mommox should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, active nasal infections, recent nasal surgery, or those for whom systemic corticosteroid therapy is contraindicated. A healthcare professional should evaluate suitability before initiating therapy.